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Background: Reprogramming energy metabolism has been an emerging hallmark of cancer cells. MicroRNAs play
important roles in glucose metabolism.
Methods: The targets of microRNA-26a (miR-26a) were predicted by bioinformatics tools. The efficacy of miR-26a
binding the 3′-untranslated region (UTR) of pyruvate dehydrogenase protein X component (PDHX) mRNA was
evaluated using a dual-luciferase reporter assay. The PDHX expression at the mRNA and protein level in several
colon cancer cell lines was quantified with real-time PCR and Western blot analysis respectively. The effects of
miR-26a on glucose metabolism were determined by detecting the content of glucose consumption, production
of lactate, pyruvate, and acetyl-coenzyme A.
Results: The expression of miR-26a is inversely associated with the level of its targeting protein PDHX in several
colon cancer cell lines with different malignancy potentials. MiR-26a inhibits PDHX expression by direct targeting
the 3′-UTR of PDHX mRNA. The glucose consumption and lactate concentration were both greatly increased in
colon cancer cells than the normal colon mucosal epithelia under physiological conditions. The overexpression of
miR-26a in HCT116 cells efficiently improved the accumulation of pyruvate and decreased the production of acetyl
coenzyme A. Meanwhile the inhibition of miR-26a expression induced inverse biological effects.
Conclusions: MiR-26a regulates glucose metabolism of colorectal cancer cells by direct targeting the PDHX,
which inhibits the conversion of pyruvate to acetyl coenzyme A in the citric acid cycle.
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Recent studies have shown that microRNAs (miRNAs)
play important roles in energy metabolism [1], and thus in
cancer cells the alterations of cellular metabolism are asso-
ciated with miRNA dysregulation [2,3]. MiRNAs partici-
pate in cell metabolism by regulating the expression of
genes whose protein products either directly regulate
metabolic machinery or indirectly modulate the expres-
sion of metabolic enzymes, serving as master regulators
[4]. For example, microRNA-195-5p [5] and microRNA-
143 [6] can repress the glucose uptake and glycolysis
processing by inhibiting the expression of glucose trans-
porter 3 (GLUT3) and hexokinase 2 respectively. And* Correspondence: zizi2006@scu.edu.cn
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unless otherwise stated.microRNA-143 could affect the glucose metabolism by
regulating the AKT signaling pathway [7].
Reprogramming energy metabolism has been an emer-
ging hallmark of cancer [8]. The best characterized
metabolic phenotype in cancer cells is the “Warburg
effect”. Even in the presence of oxygen, cancer cells can
reprogram their glucose metabolism, and thus the ATP
generation shifts from oxidative phosphorylation to gly-
colysis, leading to a state termed “aerobic glycolysis” [9].
Unlike normal cells, cancer cells usually derive a sub-
stantial amount of energy from aerobic glycolysis by
converting most incoming glucose to lactate rather than
metabolizing it through oxidative phosphorylation. Al-
though ATP production via glycolysis can be more rapid
than by oxidative phosphorylation, the ATP generated is
far less for per unit of glucose consumed. As a result,
this shift demands that cancer cells implement antd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 MiR-26a targets the 3′UTR of PDHX mRNA directly.
A(I) The miR-26a matches the eight nucleotide sequences (468-475 nt,
UACUUGAA) of the 3′ UTR of the PDHX mRNA; A(II) The 3′UTR of PDHX
mRNA was amplified and the cDNA fragment was cloned to construct
the wild type recombinant plasmid pwt-PDHX, which contains the
eight nucleotide sequences (…TACTTGAA…); A(III) The relevant eight
nucleotides (…TACTTGAA…) were mutated to a random sequence
(…TCACCAAT…) to construct the mutant recombinant plasmid
pmt-PDHX. B. The miR-26a targets the 3′ UTR of PDHX mRNA analyzed
by the luciferase reporter assays. Both of the two luciferase signals were
measured and the activity of the Renilla luciferase was normalized to
the firefly luciferase to generate the normalized Renilla luciferase
activity. In the case of pwt-PDHX (left), the expression of miR-26a
reduced luciferase activity effectively, while the luciferase activity was
not inhibited in the case of the pmt-PDHX (right). Data are shown as
the mean ± the standard error of the mean (SEM) of three replicates.
P-value was computed using the Student’s t-test. *p < 0.05. pwt-PDHX:
wild type recombinant plasmid of 3′UTR of PDHX mRNA; pmt-PDHX:
mutant recombinant plasmid of 3′UTR of PDHX mRNA; pENTR-miR-26a:
the miR-26a expression plasmid; pENTR-MIRNA: the empty vector
without miR-26a.
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creased energy and biosynthesis. By now, several studies
have focused on miRNA contributions to the “Warburg
effect” [1,3], and many molecules regulated by miRNAs
are investigated.
MicroRNA-26a (miR-26a) shows a higher expression
level in colon cancer tissues than in normal colon tissues
[10], and its expression is also elevated under hypoxia
conditions [11]. Meanwhile, miR-26a has been reported
to play functions in cellular differentiation, cell growth,
cell apoptosis and metastasis [12-15]. However, none of
these studies on miRNA-26a focuses on energy metabol-
ism. Several glycolysis genes, including glyceraldehyde-
3-phosphate dehydrogenase, phosphoglycerate kinase 1
and phosphoglycerate mutase 1, have up-regulation in
colon cancer tissues [16], therefore colon cancer cells
have a higher glycolytic rate compared with normal cells
[17]. In this study, we aim to discover the function of
miR-26a on glucose metabolism in colorectal cancer
cells. We have identified the pyruvate dehydrogenase
protein X component (PDHX) as a direct target of miR-
26a that is involved in the biological processes of glucose
metabolism in colorectal cancer (CRC) cells.
Methods
Cell culture
The CRC cell lines including SW620, SW480 and HCT116
were ordered from American Type Culture Collection.
The cell line NCM460, which is derived from normal
human colon mucosal epithelium, was ordered from the
INCELL Corporation, LLC, USA (www.incell.com). The
cells were all cultured in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal bovine
serum at 37°C in humidified atmosphere with 5% (v/v) CO2.
Prediction of candidate miRNA targets
The alignment of the miR-26a seed region and 3′-un-
translated regions (UTR) of PDHX mRNA of different
species were analyzed as literatures described previously
[6,18]. The possible targets of miR-26a were screened by
bioinformatics tools, Pictar (http://pictar.mdc-berlin.de)
and TargetScan (http://www.targetscan.org).
Construction of expression plasmids
A 461-bp nucleotide fragments in pre-miR-26a sequences
(Additional file 1: Table S1) were cloned into the pENTR-
CMV-EGFP vector (ordered from Wuhan Cell marker
Biotechnology Co., Ltd., Wuhan, P. R. China) between
XhoI and EcoRI to construct miR-26a expression plasmid,
pENTR-miR-26a. The empty vector pENTR-MIRNA was
used as a control in the ectopic overexpression of miR-26a.
The 3′-untranslated region (3′UTR) of PDHX mRNA
(Additional file 2: Table S2) was amplified by RT-PCR.
The cDNA fragment corresponding to the 3′UTR ofPDHX mRNA was cloned in the downstream of the
Renilla luciferase gene in the psiCHECK-2 vector (Cat. #
C8021, Promega, USA), which contains a reporter gene
Renilla luciferase and an intraplasmid transfection normalization
gene, a firefly luciferase. The 3′UTR of PDHX mRNA
contains eight nucleotides (5′…UACUUGAA…3′), which
are corresponding to miR-26a seed sequences (3′…
AUGAACUU 5′) (Figure 1A(I)). In the wild type recom-
binant plasmid pwt-PDHX, the relevant eight nucleotides
(…TACTTGAA…) were involved (Figure 1A(II)). Mean-
while, in the mutant recombinant plasmid pmt-PDHX
(Figure 1A(III)), the eight nucleotides were mutated into a
random nucleotide sequence (…TCACCAAT…).
Cells treated with MiR-26a inhibitor
The miR-26a inhibitor was commercially available chem-
ically modified antisense oligonucleotide inhibitor (Prod-
uct ID: MH10249, Cat. #4464084, Life Technologies
Corporation, USA). The non-targeting oligonucleotides
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as a negative control, were also ordered from this
company.
The miR-26a inhibitor or the negative control was
respectively transfected at a working concentration of 30
nM using Lipofectamine 2000 reagent (Cat. #11668-019,
Invitrogen). The ratio of Lipofectamine 2000 reagent
(μL) versus the oligonucleotides (pmol) was 18:1.
RNA extraction and real-time PCR
Total RNA was extracted using Trizol reagent (Cat. #15596-
026, Invitrogen). The total RNA was dissolved with RNase-
free water for use. The first-strand cDNA for miR-26a was
generated using a cDNA synthesis kit (Cat. #K1622, Thermo
Scientific). Specific primers were designed for the reverse
transcription of miR-26a and U6. The primer sequences for
miR-26a were TGTCAACGATACGCTACCTAACGGCAT-
GACAGTGTCAGCCTA. And the primer for U6 was
GAACGCTTCACGAATTTGC based on literature reports
[13]. For PDHX, random primers were used for mRNA
reverse transcription (Cat. #170-8890, Bio-Rad).
The real-time PCR was performed to measure the relative
expression using the Supermix-Bio-Rad kit (Cat. #172-5261,
Bio-Rad) following the protocol. The U6 was used as an
internal reference to calculate the relative expression level of
miRNA, and the GAPDH mRNA level was taken as a com-
parison base for the target RNA expression. The relative
RNA expression was calculated with the comparative CT
method, which was normalized to the internal references.
The forward RT-PCR primer for PDHX was 5′-GTC
CCTCTAAAGCAGCTCAAAA-3′, and the reverse one
was 5′-CTCCCTTCAAAAGATCCAACTG-3′. The for-
ward one for miR-26a was 5′-CTGTCAACGATACGCT
AC-3′, and its reverse was 5′-GTAATCCAGGATAG
GCTG-3′. In addition, the forward RT-PCR primer for U6
was 5′-CTTCGGCAGCACATATAC-3′, meanwhile its re-
verse primer was 5′-GAACGCTTCACGAATTTGC-3′.
Cell transfection
The miR-26a expression plasmid pENTR-miR-26a or the
empty vector pENTR-MIRNA was respectively trans-
fected at a working concentration of 100 nM using Lipo-
fectamine 2000 reagent (Cat. #11668-019, Invitrogen).
The ratio of DNA (μg) versus the Lipofectamine 2000
reagent (μL) was 1: 2.
For the promoter luciferase reporter assay, the plasmid
pwt-PDHX or pmt-PDHX was co-transfected with the
miR-26a expression vector pENTR-miR-26a or the
empty vector pENTR-MIRNA into HEK293T cells. As
mentioned above, Lipofectamine 2000 was used as the
transfection reagent. The plasmid was used at a working
concentration of 100 nM as well. The ratio of plasmid
DNA (μg) versus the Lipofectamine 2000 reagent (μL)
was 1: 2.Western blot analysis
The protein PDHX was detected against its specific anti-
body by western blot. The PVDF membranes were re-
spectively incubated with the primary antibody of PDHX
(diluted 1:1000, Cat. # S0394, Epitomics, USA) at 4°C
overnight, followed by incubating with a secondary
HRP-conjugated antibody at 37°C for 1 h. Signal detec-
tion was performed with Luminata Crescendo Western
HRP Substrate (Cat. # WBLUR0100, Millipore). The de-
tection of GAPDH using its antibody (Cat. # sc-365062,
Santa Cruz Biotechnology) was taken as a control.
Luciferase reporter assay
Either the plasmid pwt-PDHX or pmt-PDHX was re-
spectively co-transfected with the miR-26a expression
vector pENTR-miR-26a into HEK293T cells, and cells
were harvested for assessment of luciferase activity at
48 hours after transfection. The luciferase activities of
cellular extracts were measured with a Dual Luciferase
Reporter Assay System (Cat. #E1910, Promega). Both
Renilla luciferase and firefly luciferase activities were
measured. The luciferase signal was normalized to the
firefly luciferase signal as described previously [19].
Measurement of glucose consumption and lactate
production
Either the pENTR-miR-26a or miR-26a inhibitor was
transfected into CRC cells. Cell culture media were col-
lected after transfection for 48 h. Glucose uptake and
lactate production were measured using Amplex® Red
Glucose/Glucose Oxidase Assay Kit (Cat. #A22189; Invi-
trogen) and lactate assay kit (Cat. #MAK064; Sigma-
Aldrich) respectively. The results were normalized on
the basis of total cellular protein amounts.
Pyruvate assay
The concentration of pyruvate in CRC cells, transfected
with pENTR-miR-26a or miR-26a inhibitor, was respect-
ively measured using pyruvate assay kit (Cat. #K609-100;
BioVision). Briefly, cells were collected after transfection
for 48 h and dissolved with 0.5 ml of pyruvate assay buf-
fer. And 50 μl sample was added with 50 μl of reaction
mixture to incubate at room temperature for 30 minutes.
A standard curve covering a range of 10–0.1 nmol per
well was used as control. Absorbance was measured at
570 nm. The pyruvate concentration, which was normal-
ized on the basis of totally cellular protein amounts, was
calculated relative to the standard curve.
Acetyl-coenzyme aassay
To analyze the production of acetyl coenzyme A (acetyl-
CoA), cell extracts were prepared using the perchloric
acid approach as described previously, with minor modi-
fication [20]. CRC cells, treated with pENTR-miR-26a or
Figure 2 PDHX is a predicted target of miR-26a. (A) Alignment
of the miR-26a seed region with 3′UTR of PDHX mRNA of different
species across Homo sapiens (Hsa), Pan troglodytes (Ptr) and Mus
musculus (Mmu). Bioinformatics analysis was performed using the
TargetScan 6.2 software available at http://www.targetscan.org. The
accession number of the protein PDHX from Has, Ptr and Mml was
NM_003477, NM_001280073, NM_175094. The miR-26a seed region
was highlighted in grey. (B) The 468–475 nt of PDHX 3′ UTR mRNA
showed an exact match to the seed region of mature miR-26a.
(C-D) MiR-26a level is inversely correlated with PDHX protein level
in CRC cells. Expression of miR-26a and PDHX protein were respectively
analyzed by qRT–PCR (C) and western blot (D). The error bar represented
the standard error of the mean (SEM). A Student’s t-test was performed
to compare the differences between NCM460 and HCT116, SW480
or SW620.
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phosphate-buffered saline. Cells were mixed in 1 mL of
washing buffer (10 mM sodium phosphate [pH 7.5],
10 mM MgCl2, 1 mM EDTA), treated with 200 μL of
3 M ice-cold HClO4, and incubated on ice for 30 mi-
nutes. The mixture was centrifuged for 5 minutes at
10,000 × g at 4°C. The supernatant was neutralized with
saturated KHCO3 and centrifuged as described above.
The level of acetyl-CoA in the cell extraction was quan-
tified using the acetyl-CoA assay kit (Cat. # K317-100;
BioVision). Fluorescence was measured (Ex/Em = 535/
589 nm), and the acetyl-CoA concentration was calcu-
lated based on the standard curve. The production of
acetyl-CoA was normalized based on the total of cellular
proteins.
Results
Bioinformatics analysis for potential targets of miR-26a
By analyzing the 3′UTR mRNA of several glycolytic
enzymes, we found that the 3′UTR of PDHX is relatively
long with around 797 nucleotides, suggesting that PDHX
mRNA is a possible target for miRNAs. In order to
predict the possible target gene of miR-26a, the miRNA
binding sites in the 3′UTR of PDHX were further ana-
lyzed through the Pictar and TargetScan software [6,18].
A conserved miR-26a binding site exists in the 3′UTR of
PDHX across Homo sapiens (Hsa), Pan troglodytes (Ptr)
and Mus musculus (Mmu) (Figure 2A), further we pre-
dicted an exact match to the seed region of mature miR-
26a (Figure 2B). The bioinformatics analysis indicated a
potential functional link between PDHX and miR-26a.
MiR-26a level is inversely associated with the protein
expression of PDHX
The expression level of miR-26a in NCM460, HCT116,
SW480 and SW620 cells was examined using q-PCR
analysis (Figure 2C). Compared with the normal epithe-
lial cells NCM460, the expression of miR-26a was sig-
nificantly increased to 1.3, 1.7 and 4.6-fold for the colon
cancer cell lines HCT116, SW480 and SW620 respect-
ively (p < 0.05). Generally, the expression level of miR-
26a was significantly higher in malignant CRC cell lines
HCT116, SW480 and SW620 than in a normal colorec-
tal mucosal epithelial cell line NCM460 [21], especially
it was almost increased over 4-fold in SW620 cells,
which has high lymph node metastatic potentials [22].
Among the three CRC cell lines, the expression levels of
miR-26a were gradually increased from HCT116 to
SW480 and SW620 cells. Compared with HCT116 cells,
which is derived from a human colorectal adenocarcin-
oma [22], SW480 and SW620 cells are typical model
systems for CRC metastasis. The SW480 is derived from
the primary site of CRC and SW620 comes from the
recurrent lymph node metastasis [23]. Therefore, it hasa positive correlation between the expression levels of
miR-26a and the malignant degree of CRC cells.
As miRNA expression is often inversely correlated
with those of their specific target mRNAs, we further
analyzed the protein expression of the miR-26a target —
PDHX, in CRC cell lines. We found that the expression
of PDHX was stepwise decreased in NCM460, HCT116,
SW480 and SW620 cells (Figure 2D). The expression
level of miR-26a in NCM460 was the lowest among the
four cell lines (Figure 2C), but the protein level of PDHX
exhibited the highest (Figure 2D). While in SW620 cells,
the highest level of miR-26a expression and the lowest
level of PDHX expression were observed. By comparing
the expression levels of miR-26a and PDHX, an inverse
correlation between them was observed in CRC cell
lines, which supported the bioinformatics prediction on
miR-26a target as above.
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Among these CRC cell lines, HCT116 cells were chosen
to perform the following studies since it showed the
media expression of miR-26a. Firstly, the miR-26a ex-
pression plasmid pENTR-miR-26a was transfected into
HCT116 cells to detect its influence on the expression
level of PDHX. As a result, a marked reduction of
PDHX was observed at both mRNA and protein level
when miR-26a was overexpressed with almost 2.5-fold
(Figure 3A). Compared to the empty vector pENTR-
MIRNA, the expression of PDHX mRNA reduced al-
most 33% (P < 0.001) in HCT116 cells transfected with
pENTR-miR-26a (Figure 3B), and PDHX protein was
decreased by almost 40% (Figure 3C).
Furthermore, the suppression of miR-26a expression
was performed in HCT116 cells treated with 30 nM
of miR-26a inhibitor, and the random oligonucleotides
were taken as negative controls. Compared with the
negative control, the mRNA expression of PDHX had a
1.3-fold upregulation (Figure 3E) in HCT116 cells, along
with about 70% inhibition of miR-26a (Figure 3D), andFigure 3 A negative correlation between the expression level of miR-
miR-26a (A) induced a significant reduction of PDHX expression both in m
pENTR-MIRNA was used as a control. While the expression of PDHX at both
with an inhibition of miR-26a expression (D). The non-targeting oligonucle
as the mock object. The mean values were calculated from three separatethe protein expression of PDHX was increased 1.5-fold
in the treated HCT116 cells (Figure 3F).
We also performed the loss-of function studies in
SW620 cells, which have a highly endogenous expression
level of miR-26a and a low level of PDHX (Figure 2C-D).
Under the condition of a great down-regulation of miR-
26a in SW620 cells (Figure 4A, p < 0.01), the mRNA ex-
pression of PDHX was significantly increased with 2-fold
(Figure 4B, p < 0.01), while the protein level of PDHX was
improved to 1.56-fold (Figure 4C). The down-regulation
of endogenous miR-26a in SW620 cells could restore
PHDX expression, which is similar to the effects with a
knock-down of miR-26a in HCT116 cells (Figure 3).
Except to the gain and loss-of function studies, the
direct regulatory effect of miR-26a on PDHX expression
was also verified by Renilla luciferase reporter gene
assays. Either the plasmid pwt-PDHX or pmt-PDHX was
co-transfected with the miR-26a-expressing pENTR-
miR-26a into HEK293T cells respectively. Cells were
harvested for assessment of luciferase activity at 48 hours
after transfection. Compared with the mutated reporter26a and PDHX in HCT116 cells. The ectopic overexpression of
RNA (B) and protein levels (C) in HCT116 cells. The empty plasmid
mRNA and protein levels (E, F) was increased in HCT116 cells along
otide was used as a control. The untreated HCT116 cells were taken
experiments. SEM: the standard error of the mean.
Figure 4 The correlation of miR-26a expression and its target
protein PDHX in SW620 cells. The expression of PDHX at both
mRNA (B) and protein levels (C) was upregulated in SW620 cells
with a decrease of endogenous miR-26a (A). The non-targeting
oligonucleotide of miR-26a was used as a control. The untreated
SW620 cells were taken as the mock object. The mean values were
calculated from three separate experiments. SEM: the standard error
of the mean.
Figure 5 The glucose consumption (A) and lactate production
(B) were measured in colorectal cancer cell lines. The error bar
represented the standard error of the mean (SEM). A Student’s t-test
was performed to compare the differences between NCM460 and
HCT116, SW480 or SW620 cells.
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PDHX was co-transfected with the miR-26a-expressing
plasmid pENTR-miR-26a, the ectopically expressing
miR-26a bound to the 3′ UTR of the wild type plasmid
pwt PDHX, then the fused luciferase and the 3′UTR of
PDHX was cleaved and subsequently degraded, which
resulted in an effective decrease of luciferase activity
(Figure 1B). By contrast, in the case of the co-transfection
of the mutant plasmid pmt-PDHX with the pENTR-miR-
26a, the ectopically expressing miR-26a couldn’t bind
to the 3′ UTR of the mutant type plasmid pmt-PDHX,
furthermore the luciferase activity did not be decreased.These data showed that miR-26a modulates the PDHX
expression by direct targeting the 3′UTR mRNA of PDHX.MiR-26a affects cell glucose metabolism
The glucose consumption and lactate production were
gradually increased among the NCM460, HCT116, SW480
and SW620 cells under physiological conditions (Figure 5).
Compared with the normal cell line NCM460, each CRC
cell line showed a high level of glucose consumption. The
glucose uptake was 30.94, 37.38, 44.42 and 110.99 μmol
respectively for NCM460, HCT116, SW480 and SW620
cells. Moreover, there is a positive correlation between the
lactate production and the malignant potential of CRC
cells. The lactate production was 38.78 μmol, 70.24 μmol,
75.63 μmol and 195.10 μmol from NCM460, HCT116,
SW480 to SW620 cells. The lactate content in NCM460
cells was much lower than each of CRC cells. Especially for
SW620 cells, it showed more than 5-fold of lactate produc-
tion than NCM460 cells. In combination with the miR-26a
endogenous level in these cells (Figure 2C), it is concluded
Figure 6 The miR-26a regulates glucose metabolism in HCT116
cells. (A) Overexpression of miR-26a, by transfection of pENTR-miR-26a in
HCT116 cells, elevated glucose uptake. The empty vector pENTR-MIRNA
was used as the control. (B) The suppressed expression of miR-26a with
its inhibitor treatment greatly induced the decrease of glucose uptake.
A non-targeting oligonucleotide was used as the control. The miR-26a
inhibits the conversion of pyruvate to acetyl-CoA in HCT116 cells.
(C, D) The pyruvate content was increased when HCT116 cells transfected
with miR-26a-expressing plasmid pENTR-miR-26a, while the acetly-CoA
production was decreased. The empty vector pENTR-MIRNA was used
as the control. (E, F) The suppressed expression of miR-26a with its
inhibitor treatment induced the decrease of pyruvate content and
the up-regulation of the acetly-CoA production. A non-targeting
oligonucleotide was used as the control. The average values ± the
standard error of the mean (SEM) of three separate experiments were
plotted. *p < 0.05, ** p < 0.005.
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a preference to glycolysis.
In order to investigate miR-26a effects in glucose usage
for colon cancer cells, the glucose uptake in HCT116 cells
was compared either under the condition of miR-26a
overexpression or inhibition. The glucose consumption
was increased from 28.86 μmol to 53.58 μmol in miR-26a-
overexpressing HCT116 cells by transfecting with pENTR-
miR-26a (Figure 6A), showing an almost 2-fold elevation
(p < 0.05). Furthermore, we performed a loss-of-function
analysis of miR-26a in glucose consumption by using
its inhibitor to silence endogenous miR-26a expression.
With loss of miR-26a expression, the glucose usage was
decreased from 18.82 μmol to 11.25 μmol after being
treated with miR-26a inhibitor compared to the control
(Figure 6B), indicating a 0.59-fold change (p < 0.005). These
evidences strongly demonstrated that the expression level
of miR-26a is positively associated with the glucose
utilization in colon cancer cells. The overexpression of
miR-26a enhanced glucose usage. On the contrary, the
inhibition of miR-26a expression would reduce glucose
consumption.
Considering the direct target molecule of miR-26a, we
further detected whether the effects of miR-26a on glu-
cose metabolism were mediated its target gene PDHX.
PDHX, also known as E3 binding protein (E3BP), is
a non-catalytic subunit of PDH complex [18,24] to
catalyze the conversion of pyruvate to acetyl-CoA, thereby
linking glycolysis to the citric acid cycle [25]. Since PDHX
plays a key role in the conversion of pyruvate to acetyl-
CoA, we further detected the concentration changes
of pyruvate and acetyl-CoA in miR-26a-overexpressing
HCT116 cells. As expected, a 1.2-fold increase of pyruvate
accumulation (from 8.90 μmol to 10.55 μmol) was detected
with the ectopic overexpression of miR-26a (Figure 6C),
while the amount of acetyl-CoA (from 474.87 μmol to
410.26 μmol) in HCT116 cells showed a 14% decrease
(Figure 6E) (p < 0.05). Besides, the expression inhibition of
endogenous miR-26a could induce the decrease of pyru-
vate content. In detail, the pyruvate content in HCT116
cells was decreased from 1.83 μmol to 0.66 μmol, reducing
about 63% (p < 0.05) after being treated with miR-26a
inhibitor (Figure 6D). While in the same conditions, the
production of acetyl-CoA was effectively increased from
464.87 μmol to 554.90 μmol, raising to almost 1.2 fold
(p < 0.05) (Figure 6F).
Similarly, we had also performed the loss-of-function
studies in SW620 cells to measure the glucose utilization,
pyruvate content and acetyl-CoA production. As shown in
Figure 7, when the endogenous miR-26a was inhibited,
the glucose uptake was decreased from 47.66 μmol to
39.50 μmol and the pyruvate content was decreased from
14.36 μmol to 2.56 μmol, with about 20% (p < 0.05) and
75% (p < 0.01) reduction respectively. While the acetyl-CoAconversion was increased from 200.28 μmol to 252.46 μmol,
with almost a 1.3-fold upregulation (p < 0.05). It indicated
that the inhibition of miR-26a in SW620 cells could cause
similar glucose metabolic effects that were obtained in
HCT116 cells.
All these results have demonstrated that miR-26a in-
hibits the conversion of pyruvate to acetyl-CoA though
directly targeting the PDHX (Figure 8), which accelerates
the glucose consumption to undergo aerobic glycolysis for
meeting their increased energy and biosynthesis in colon
cancer cells.
Figure 7 The miR-26a regulates glucose metabolism in SW620 cells. (A) The suppressed expression of miR-26a with its inhibitor treatment
greatly induced the decrease of glucose uptake. A non-targeting oligonucleotide was used as the control. The miR-26a inhibits the conversion of
pyruvate to acetyl-CoA in SW620 cells. (B, C) The suppressed expression of miR-26a with its inhibitor treatment induced the decrease of pyruvate
content and the up-regulation of the acetly-CoA production. A non-targeting oligonucleotide was used as the control. The average values ± the
standard error of the mean (SEM) of three separate experiments were plotted. *p <0.05, **p < 0.005.
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The role of miR-26a in carcinogenesis appears to be a
complicated one, in the sense that both oncogenic and
tumor suppressive effects were reported in cancers. For
example, miR-26a enhances lung cancer cell metastasis
potential via activating AKT pathway by phosphatase
and tensin homolog (PTEN) suppression [26]. Other
studies find that miR-26a suppresses cell growth and
metastasis through IL-6-Stat3 signaling in hepatocellular
carcinoma [27]. Our study showed that miR-26a has
an increased level in CRC cells, especially it has much higher
expression in high-metastasis SW620 cells (Figure 2C). TheFigure 8 The molecular mechanism of miR-26a involved in
glucose metabolism in CRC cells. MiR-26a directly targets the
PDHX to suppress the conversion of pyruvate to acetyl-CoA, thus
blocking the key step of glycolysis to the citric acid cycle. “┤”
represents the inhibition effect.finding indicates miR-26a has an oncogenic role in the
carcinogenesis of CRC.
More importantly, we also discovered the molecular
mechanism of miR-26a involved in glucose metabolism of
colon cancer cells. The miR-26a inhibits the expression of
PDHX by direct targeting the conserved miR-26a recogni-
tion motif of the 3′UTR of PDHX mRNA, which efficiently
decreases the process of pyruvate-acetyl-CoA conversion
and thus blocks the key step of glycolysis to the citric acid
cycle in glucose metabolism. The PDHX is a non-catalytic
subunit of the PDH complex, which is located in the mito-
chondrial matrix and is central to mitochondrial fuel me-
tabolism [28]. The PDH complex catalyzes the irreversible
oxidation of pyruvate to acetyl CoA, a rate-limiting step
under aerobic conditions for the oxidative removal of glu-
cose and pyruvate and for other 3-carbon metabolites (ala-
nine and lactate) in equilibrium with pyruvate [29]. Except
to the non-catalytic subunit PDHX, the PDH complex
contains three catalytic subunits (pyruvate dehydrogenase
E1, dihydrolipoamide transacetylase E2 and dihydrolipoa-
mide dehydrogenase E3) and two regulatory subunits
(E1 kinase and E1 phosphatase). It is known that PDHX is
required for tethering E3 dimers to the E2 core and this
specific binding is essential for a functional PDH complex.
Our results provided experimental evidences to verify the
bioinformatics speculation that miR-26a has a high possi-
bility to regulate PDHX in lung cancer [3]. So far, it is the
first report to explore the miR-26a-regulated glucose
metabolism via targeting PDHX in CRC, which is helpful
for understanding miRNA functions in the biochemical
processes of the Warburg effect in tumors.
Glucose utilization was changed significantly in HCT116
cells when miR-26a was ectopically overexpressed or inhib-
ited. It seems that miR-26a might prompt glucose uptake
to meet the need of energy and biosynthesis in cancer cells.
Most mammalian cells import glucose by a process of fa-
cilitative diffusion mediated by members of GLUTs family
[30]. The effects of miR-26a on the expression and/or the
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ing to further investigate in our following research.
Furthermore, growing evidence has shown that cancer cell
metabolism is also controlled by external responses to
the tumour microenvironment [9]. For example, cancer-
associated fibroblasts have been reported to undergo
Warburg metabolism and mitochondrial oxidative stress
[31]. They are possibly correlated with metabolic repro-
gramming of cancer cells toward Warburg metabolism by
rapidly expressing carbonic anhydrase IX, which could
result in extracellular acidification [32]. These factors will
be considered in our further study.
Recently, microRNA molecules are already entering the
clinic as potential diagnostic and prognostic biomarkers,
as well as therapeutic targets or agents [33]. The miRNAs
as important regulators of metabolism have garnered
much interest not only from a scientific point of view but
also from a clinical perspective [1]. The function of miR-
NAs on cellular metabolism reveals molecular strategies
for controlling metabolic flux by miRNAs in living organ-
isms, thus lighting up one aspect of miRNA therapeutics.
The use of miRNAs, such as oligonucleotide complemen-
tary [34] or antisense oligonucleotides [35] in miRNA
inhibition, to suppress cell metabolism altering will hope-
fully lead to a new therapeutic strategy for malignant
cancer [36,37]. A high rate of glycolysis to obtain energy is
a commonly observed feature in cancers, and previous
studies usually focus on miRNA roles in targeting the key
enzymes of glycolysis, including hexokinase-2 [3], and
pyruvate dehydrogenase kinase [38,39]. Our data indicated
that miR-26a also regulates the process of pyruvate-acetyl-
CoA conversion which is the former reaction of entering
the citric acid cycle. Previous studies have shown that
miR-26a is significantly associated with disease progres-
sion and therapy response in CRC [39-42]. Therefore, the
miR-26a is a potential cancer therapeutic target by regulat-
ing glucose metabolism in CRC, which also provides a
promising anti-neoplasia strategy.
Conclusions
The expression levels of miR-26a are associated with the
malignant degrees of CRC cells. MiR-26a has key roles in
regulating glucose metabolism by direct targeting PDHX
in CRC cells , which inhibits the conversion of pyruvate to
acetyl CoA in tricarboxylic acid cycle. These novel findings
are helpful for understanding the CRC development and
indicate a promising anti-neoplasia strategy.
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